Clinical trial · Observational
Secondary Prognostic Index in RefrActory Lymphoma
Secondary Prognostic Index in RefrActory Diffuse Large B Cells Lymphoma
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
60% of patients with diffuse large B cell lymphoma are healed after first-line treatment which whatever the age. For the remaining 40% of patients (relapses and primary refractories): * 38% of patients will be cured with a 2nd line including an autologous haematopoietic cell transplantation for those under 65 years. * for older patients who are not eligible for a autograft: only 70% of patients will be able to receive 2nd line treatment with rates response less than 50%. * the survival rate in patients receiving 3rd line treatment or more is 15% at 2 years. Actually, no standard of chemotherapy is offered to relapsed or refractory patients after 2 therapeutic lines. Subsequent lines lead to hospitalizations for infectious complications or transfusions without clear clinical benefit with often an impacted quality of life. Palliative care is rarely offered as part of the treatment overall load.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Diffuse Large B Cell Lymphoma | Diffuse Large B-Cell Lymphoma | CURATED_BROADER | 0.80 |
| Refractory Diffuse Large B-Cell Lymphoma | Diffuse Large B-Cell Lymphoma | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| prognostic assessment | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- population
- description
- The population includes adult patients. * Patients died from refractory or relapsed diffuse large-cell lymphoma. * Patients \<65 years of age eligible for an autologous transplant should have relapsed after the autologous transplant. * Patients \>65 years of age or not eligible after an autologous transplant must have received at least one RCHOP-type treatment line (2 cycles).
- interventionNames
- Other: prognostic assessment
Primary outcomes (1)
- measure
- Overall survival
- timeFrame
- 5 years
- description
- Time between the date of relapse or no response observed (after 2 lines of chemotherapy in young patients and one line for elderly patients) and the date of death regardless of the cause.
Secondary outcomes (4)
- measure
- Median response time after each line
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age \> 18 years old * died of diffuse large B cell lymphoma * Refractory or relapsing after 2 treatment lines for young patients (RCHOP then recovery with platinum salts and autograft) and one line for elderly patients (RCHOP) Exclusion Criteria: * patients with HIV infection * solid tumor treated less than 5 years ago with the exception of skin carcinoma or carcinoma in situ of the uterine cervix treated locally * inclusion in a therapeutic trial
References
Publications (0)
Data not yet available